ALVIZON™ Breakthrough Potential Confirmed.

ALVIZON™ has achieved compelling Phase IIa results in Geographic Atrophy (GA), demonstrating strong signals of efficacy alongside an excellent safety profile, positioning the program as a high-value clinical and commercial opportunity.

Independently reviewed and cleared by the DSMB, the data confirm statistically significant improvements across multiple functional and anatomical endpoints, with **no** safety issues.

Strong Functional Vision Gains

ALVIZON™ delivered significant improvements in visual acuity:

- Statistically significant improvement in Low Luminance Visual Acuity (LLVA) (p = 0.001), indicating enhanced retinal function.

This demonstrates both functional gain and stabilisation, in the absence of adverse events, addressing a ***major unmet need***. GA is the end stage of the world's leading cause of blindness.

Clear Signal of Efficacy

- Significant reduction (>50%) in GA lesion growth rate (p = 0.001) vs published untreated controls.

These combined results confirm ALVIZON™'s therapeutic mode of action.

Best-in-Class Safety Profile

- No treatment-related adverse events observed.
- No clinically significant IOP increase.

Differentiated Product Profile

Combines efficacy, safety, and convenience:

- Novel mechanism of action.
- Controlled intraocular dwell time.
- Quarterly dosing (every 3 months), reducing treatment burden and healthcare costs.

Professor Andrew Chang AM MBBS(Hons) PhD, FRANZCO FRACS, **Medical Director Sydney Eye Hospital**, commented that: "corticosteroids target upstream inflammation and may enable longer-acting, less frequent treatments compared to current complement inhibitors. This has the potential to reduce patient burden."

Positioned for Value Creation

Eye Co has systematically de-risked the program through preclinical (Experimental Eye Research, 2021) and Phase Ib validation (BMJ, 2022) and confirmed safety and efficacy in this Phase IIa.
Patents granted in the USA, Europe, Japan and Australia.
The Phase IIa data will be submitted to a peer-reviewed journal for publication.

In this study, nine patients were treated at three-month intervals over six months.
The next milestone - a 120-patient, 12-month study—represents a major value inflection point and a transaction catalyst.

Eye Co is actively seeking capital to complete Phase II and unlock significant commercial and strategic value.

Peter Abrahamson
17 June 2026.

Eye Co Pty Ltd
Level 1, 70 Doncaster Road
Balwyn North VIC 3104, Australia
www.eyeco.com.au/

Phase IIa Data Summary

Low Luminance Visual Acuity



Enhanced Retinal Function:
Statistically significant improvement in low-light vision (p=.001)

Best Corrected Visual Acuity



BCVA improved by 5.4 letters
(95% CI 0.2 to 10.6 letters, P = 0.04).

Intra-ocular Pressure (IOP)



No Clinically Significant IOP Increase

Geographic Atrophy Lesion



Significant slowing of lesion expansion
(vs published untreated controls)

Eye Co Pty Ltd
Level 1, 70 Doncaster Road
Balwyn North VIC 3104, Australia
www.eyeco.com.au/